MaxCyte, Inc. operates as a cell-based therapies and life sciences company in the United States and internationally. Its transfection systems include MaxCyte STX, a scalable transfection system that uses flow electroporation technology for the engineering of cells for a range of applications; MaxCyte VLX, an instrument for large volume cell-engineering; and MaxCyte GT, a non-viral cell-engineering technology designed for clinical use. The company also provides single use sterile processing assemblies; and proprietary electroporation buffers; and ExPERT brand series of instruments and consumables, as well as insourcing services. In addition, it develops CARMA, a novel and proprietary technology for the development of non-viral, human messenger RNA-based, chimeric antigen receptor or T-cell receptor redirected immune cell therapies. The company licenses and sells its instruments and technology; and sells its products to drug developers and biopharmaceutical companies. It has a clinical and commercial license agreement with Allogene Therapeutics, Inc. The company was founded in 1998 and is headquartered in Gaithersburg, Maryland.
IPO Year: 2021
Exchange: NASDAQ
Website: maxcyte.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/29/2023 | $7.00 | Buy | Craig Hallum |
| 10/15/2021 | Outperform | Cowen | |
| 8/24/2021 | $36.00 | Outperform | Wedbush |
| 8/24/2021 | Outperform | William Blair | |
| 8/24/2021 | $19.00 | Overweight | Stephens |
| 8/24/2021 | Outperform | Cowen & Co. | |
| 8/24/2021 | $18.00 | Buy | Stifel |
| 8/24/2021 | $22.00 | Buy | BTIG |
Craig Hallum initiated coverage of MaxCyte with a rating of Buy and set a new price target of $7.00
Cowen resumed coverage of MaxCyte with a rating of Outperform
Wedbush initiated coverage of MaxCyte with a rating of Outperform and set a new price target of $36.00
William Blair initiated coverage of MaxCyte with a rating of Outperform
Stephens initiated coverage of MaxCyte with a rating of Overweight and set a new price target of $19.00
Cowen & Co. initiated coverage of MaxCyte with a rating of Outperform
Stifel initiated coverage of MaxCyte with a rating of Buy and set a new price target of $18.00
BTIG initiated coverage of MaxCyte with a rating of Buy and set a new price target of $22.00
4 - MAXCYTE, INC. (0001287098) (Issuer)
ROCKVILLE, Md., Jan. 13, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT)), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today provided a preliminary update on financial results for the fourth quarter and full year ended December 31, 2024. Preliminary Unaudited Fourth Quarter and Full Year 2024 Results Core revenue in the fourth quarter is expected to be between $8.3 million and $8.5 million, compared to $7.2 million in the fourth quarter of 2023Core revenue for the full year is expected to be between $32.2 million and $32.4 million com
ROCKVILLE, Md., Dec. 22, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT)), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that Art Mandell has retired from his position as a member of the Board of Directors of MaxCyte effective December 31, 2024. Mr. Mandell has served on the Board since 2006 and has been an integral part of MaxCyte's growth and strategic direction. Upon Mr. Mandell's retirement, MaxCyte will have nine directors. During Mr. Mandell's tenure, MaxCyte has achieved significant milestones including its initia
ROCKVILLE, Md., Dec. 08, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT)), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced the completion of an internal operational review, initiated earlier this year following the appointment of Maher Masoud as President and Chief Executive Officer. This "bottom-up" review focused on optimizing new product development, manufacturing, commercial execution, and capital allocation to enhance efficiency and align resources with strategic priorities. As part of an effort to streamline operations,
ROCKVILLE, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT)), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, marks the 25th anniversary of its founding this year. Over the past quarter-century, the company has remained steadfast in its mission to provide the life sciences community with the necessary technologies, as well as scientific, technical and regulatory support, to develop biomedical innovations that will transform human health. "Since the Company's inception, MaxCyte set out to commercialize Flow Electroporation® te
ROCKVILLE, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ:MXCT, LSE: MXCT)), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics, today announced its financial results for the third quarter ended September 30, 2024, and updated its 2024 guidance. Third Quarter and Recent Highlights Total revenue of $8.2 million in the third quarter of 2024, an increase of 2% over the third quarter of 2023.Core business revenue of $8.1 million in the third quarter of 2024, an increase of 23% over the third quarter of 2023.No material Strategic Platform License (S
ROCKVILLE, Md., Oct. 31, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT)), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, today announced Company management will participate at two upcoming investor conferences. Stifel 2024 Healthcare ConferenceFireside Chat on Monday, November 18th at 10:55 AM ET Stephens Annual Investment ConferenceFireside Chat on Tuesday, November 19th at 3:00 PM CT A live and archived webcast of the event will be available on the "Events" section of the MaxCyte investor relations website at https://investors.
ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced the appointment of Cynthia Collins to the Company's Board of Directors as a non-executive director, effective October 14, 2024. Collins will serve on the board's compensation committee. Following her appointment, MaxCyte's total Board of Directors will increase to 10 members. "I am pleased to welcome Cynthia to MaxCyte's Board of Directors," said Mahe
ROCKVILLE, Md., Oct. 11, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, today announced that it will release financial results for the third quarter 2024 after the U.S. market close on Wednesday, November 6th, 2024. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time. Earnings Conference Call DetailsInvestors interested in listening to the conference call are required to register online. It is reco
ROCKVILLE, Md., Oct. 10, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced the appointment of Ali Soleymannezhad as Chief Commercial Officer, effective as of September 11, 2024. In his new role, Mr. Soleymannezhad will lead MaxCyte's commercial operations to increase adoption of the ExPERT Platform, provide best-in-class scientific, technical and regulatory support to customers, and expand the Company's market impact in Cell and
ROCKVILLE, Md. and SOUTH SAN FRANCISCO, Calif., Sept. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, and Kamau Therapeutics, a clinical-stage stem cell therapy gene correction company, today announced they are entering into a strategic platform license (SPL) agreement. Under the terms of the agreement, Kamau obtains non-exclusive research, clinical and commercial rights to use MaxCyte's Flow Electroporation® technology and ExPERT™ platfo
8-K - MAXCYTE, INC. (0001287098) (Filer)
8-K - MAXCYTE, INC. (0001287098) (Filer)
8-K - MAXCYTE, INC. (0001287098) (Filer)
10-Q - MAXCYTE, INC. (0001287098) (Filer)
8-K - MAXCYTE, INC. (0001287098) (Filer)
8-K - MAXCYTE, INC. (0001287098) (Filer)
10-Q - MAXCYTE, INC. (0001287098) (Filer)
8-K - MAXCYTE, INC. (0001287098) (Filer)
8-K - MAXCYTE, INC. (0001287098) (Filer)
10-Q - MAXCYTE, INC. (0001287098) (Filer)
SC 13G/A - MAXCYTE, INC. (0001287098) (Subject)
SC 13G/A - MAXCYTE, INC. (0001287098) (Subject)
SC 13G - MAXCYTE, INC. (0001287098) (Subject)
SC 13G/A - MAXCYTE, INC. (0001287098) (Subject)
SC 13G - MAXCYTE, INC. (0001287098) (Subject)
SC 13G - MAXCYTE, INC. (0001287098) (Subject)
SC 13G/A - MAXCYTE, INC. (0001287098) (Subject)
SC 13G - MAXCYTE, INC. (0001287098) (Subject)
SC 13G/A - MAXCYTE, INC. (0001287098) (Subject)
SC 13G/A - MAXCYTE, INC. (0001287098) (Subject)
4 - MAXCYTE, INC. (0001287098) (Issuer)
4 - MAXCYTE, INC. (0001287098) (Issuer)
4 - MAXCYTE, INC. (0001287098) (Issuer)
4 - MAXCYTE, INC. (0001287098) (Issuer)
4 - MAXCYTE, INC. (0001287098) (Issuer)
4 - MAXCYTE, INC. (0001287098) (Issuer)
3 - MAXCYTE, INC. (0001287098) (Issuer)
4 - MAXCYTE, INC. (0001287098) (Issuer)
4 - MAXCYTE, INC. (0001287098) (Issuer)
4 - MAXCYTE, INC. (0001287098) (Issuer)
ROCKVILLE, Md., Dec. 08, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT)), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced the completion of an internal operational review, initiated earlier this year following the appointment of Maher Masoud as President and Chief Executive Officer. This "bottom-up" review focused on optimizing new product development, manufacturing, commercial execution, and capital allocation to enhance efficiency and align resources with strategic priorities. As part of an effort to streamline operations,
ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced the appointment of Cynthia Collins to the Company's Board of Directors as a non-executive director, effective October 14, 2024. Collins will serve on the board's compensation committee. Following her appointment, MaxCyte's total Board of Directors will increase to 10 members. "I am pleased to welcome Cynthia to MaxCyte's Board of Directors," said Mahe
ROCKVILLE, Md., Oct. 10, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced the appointment of Ali Soleymannezhad as Chief Commercial Officer, effective as of September 11, 2024. In his new role, Mr. Soleymannezhad will lead MaxCyte's commercial operations to increase adoption of the ExPERT Platform, provide best-in-class scientific, technical and regulatory support to customers, and expand the Company's market impact in Cell and
STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.Hans Schikan has been a member of the Board since 2018 and is a leader in rare disease drug development and strategy. He was previously CEO of Prosensa (NASDAQ:RNA), a company developing therapies for rare diseas
ROCKVILLE, Md., Jan. 08, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, today provided a preliminary update on financial results for the fourth quarter and full year ended December 31, 2023. Preliminary Unaudited Fourth Quarter and Full Year 2023 Results Total revenue for the fourth quarter of 2023 is expected to be between $15.5 million and $15.7 million, compared to $12.4 million in the fourth quarter of 2022. Core revenue is expected to be be
ROCKVILLE, Md., Jan. 01, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, is pleased to confirm the appointment of Maher Masoud as President and Chief Executive Officer of MaxCyte effective as of January 1, 2024. In addition, Mr. Masoud now serves as a director on MaxCyte's Board of Directors. Regulatory Pursuant to Rule 17 of the AIM Rules for Companies ("AIM Rules") and Schedule Two Paragraph (g) of the AIM Rules, Mr. Maher Issa Masoud, aged 48 d
Doug Doerfler, President and CEO, to Retire Effective December 31, 2023; will continue to serve as an advisor to MaxCyte Maher Masoud, EVP, Head of Global Business Development and Chief Counsel, to Succeed Mr. Doerfler as President and CEO, Effective January 1, 2024 MaxCyte is reiterating 2023 expected core business revenue of $28-30 million, and the Company now expects to exceed prior SPL program-related guidance, with revenue of at least $10 million ROCKVILLE, Md., Dec. 11, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commer
ROCKVILLE, Md., Sept. 06, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, today announced the appointment of Ali Soleymannezhad as Executive Vice President of Bioprocessing, effective August 21, 2023. Mr. Soleymannezhad will lead global product development and marketing strategy for MaxCyte's bioprocessing business. The bioprocessing business is anchored by the STx and VLx platforms supporting biotherapeutic research, development and man
ROCKVILLE, Md., March 27, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, today announced Douglas J. Swirsky has been appointed as the Company's Chief Financial Officer, effective immediately. Mr. Swirsky is a seasoned financial leader with over two decades of experience in the healthcare sector, including as a public company executive at Nasdaq-listed organizations. "We are excited to welcome Douglas to MaxCyte where he brings exceptio
ROCKVILLE, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ:MXCT, LSE: MXCT)), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics, today announced its financial results for the third quarter ended September 30, 2024, and updated its 2024 guidance. Third Quarter and Recent Highlights Total revenue of $8.2 million in the third quarter of 2024, an increase of 2% over the third quarter of 2023.Core business revenue of $8.1 million in the third quarter of 2024, an increase of 23% over the third quarter of 2023.No material Strategic Platform License (S
ROCKVILLE, Md., Oct. 11, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, today announced that it will release financial results for the third quarter 2024 after the U.S. market close on Wednesday, November 6th, 2024. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time. Earnings Conference Call DetailsInvestors interested in listening to the conference call are required to register online. It is reco
ROCKVILLE, Md., Aug. 06, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, today announced its financial results for the second quarter ended June 30, 2024, and updates its 2024 guidance. Second Quarter and Recent Highlights Total revenue of $10.4 million in the second quarter of 2024, an increase of 15% over the second quarter of 2023.Core business revenue of $7.6 million in the second quarter of 2024, a decline of 9% over the second quarter of 20
ROCKVILLE, Md., July 09, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, today announced that it will release financial results for the second quarter 2024 after the U.S. market close on Tuesday, August 6th, 2024. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time. Earnings Conference Call DetailsInvestors interested in listening to the conference call are required to register online. It is recom
ROCKVILLE, Md., May 07, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, today announced its first quarter ended March 31, 2024 financial results and updated its 2024 guidance. First Quarter Highlights Total revenue of $11.3 million in the first quarter of 2024, an increase of 32% over the first quarter of 2023.Core business revenue of $8.2 million in the first quarter of 2024, an increase of 5% over the first quarter of 2023.Strategic Platform Li
ROCKVILLE, Md., April 10, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, today announced that it will release financial results for the first quarter 2024 after the U.S. market close on Tuesday, May 7th, 2024. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time. Earnings Conference Call DetailsInvestors interested in listening to the conference call are required to register online. It is reco
ROCKVILLE, Md., March 12, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, today announced its fourth quarter and full year ended December 31, 2023 financial results and reiterated its 2024 guidance. Fourth Quarter and Full Year Highlights Total revenue of $15.7 million in the fourth quarter of 2023, an increase of 26% over the fourth quarter of 2022.Core business revenue of $7.2 million in the fourth quarter of 2023, a decline of 32% over the fou
ROCKVILLE, Md., March 04, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, today provided revenue guidance for the full year of 2024 and reaffirmed 2023 preliminary results previously announced in January. 2023 Preliminary ResultsTotal revenue for the fiscal year of 2023 is expected to be between $41.1 million and $41.3 million, compared to $44.3 million for fiscal year 2022. Core revenue is expected to be between $29.6 million and $29.8 million, c
ROCKVILLE, Md., Feb. 09, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, today announced that it will release financial results for the fourth quarter and full year 2023 after the U.S. market close on Tuesday, March 12th, 2024. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time. Earnings Conference Call DetailsInvestors interested in listening to the conference call are required to register online.
ROCKVILLE, Md., Nov. 08, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, today announced financial results for the third quarter ended September 30, 2023. Third Quarter and Recent Highlights Total revenue of $8.0 million in the third quarter of 2023, a decrease of 25% compared to the third quarter of 2022.Core business revenue of $6.6 million in the third quarter of 2023, a decrease of 33% compared to the third quarter of 2022.SPL Program-related